Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Wound Management Technologies — Investor Presentation (March 2010)
20 slides from Sanara Medtech's investor presentation, Mar 1, 2010
Slide 1: Wound Management Technologies, Inc.
woundmanagement technologies,inc. aithgechnology Solutions RAPIDLY GROWING PROVIDER ALTY CAL PRODUCTS, ADVANCE! BIOTECHNOLOGY SOLUTIONS A $; LEADING LICENSOR, ‘O HEALTHCARE
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this Presentation are made as of the date of this Presentation unless stated otherwise and are subject to change, completion, or amendment without notice. Neither the delivery of this Presentation at any time shall under any circumstances create an implication tha
Slide 3: Executive Overview
Executive Overview Wound Management Technology, Inc. (WNDM) is a rapidly growing provider of advanced biotechnology products and eHealth technology solutions. >» WNDM is dually quoted on the OTCBB and Pink Sheets Market capitalization: @ $39.52M Shares Outstanding: 32,937,310 Shareholders : 2,048 Re
Slide 4: Executive Overview (2)
Executive Overview (2) > Primary focus: Licensing and distribution of proprietary biotech products in the US and internationally > Products: — CellerateRX®, a patented activated form of collagen, that is a disruptive technology in the $3.2B worldwide advanced wound care market. + The only collagen o
Slide 5: Executive Overview (3)
Executive Overview (3) > New Diversification / Secondary Focus: Secure eHealth and its secure messaging and notification tools will revolutionize secure healthcare communications > Financial Strategy: WNDM is expanding its product offerings to leverage its growing sales channels of domestic independ
Slide 6: Sales Estimates
- Sales Estimates Thousands : | | Nletincome P r pg (acl il | 7,080,000 » | Gross Sales, "540,000 | 11,800,000 4 Growth is based on success in new rep channels; internationé markets, and expanded product offerings. 02/2010 Numbers represent managements expectations based on current events,
Slide 7: Core Revenue Stream - CellerateRX
Core Revenue Stream - CellerateRX© > Sold through WCI, a wholly-owned subsidiary > Products are in the $3.2 B worldwide Advanced Wound Care market segment » CellerateRX is the only Activated Collagen on the market > WCI has the exclusive medical marketing rights to CellerateRX medical products for t
Slide 8: New Products in Development
New Products in Development > New formula with CellerateRX® plus other ingredients to target shingles pain reduction — Target date late 2010, early 2011 > Bone Wax and Bone Growth Stimulators — Process underway to file 510(k)s. Time to market = 6-7 months — Aresorbable orthopedic hemostat (resorbabl
Slide 9: Biotech Sales & Marketing Channels, New Domestic Relationships
Biotech Sales & Marketing Channels, New Domestic Relationships > IMCO - a major global healthcare products distributor added to WCl’s distributors (over 900 field sales reps) > Med Pro Associates - sales to long term care facilities and other healthcare segments — Training of first group in 4Q 2009
Slide 10: Market Segment Penetration
Market Segment Penetration Diabetes Specific * * New Diabetic specific website in development Consumers | * Long Term Care Facilities pictselisirvall areasin addition rr toidentified ¥ + Physicians rofrtceraites, i + Podiatrists formal Medical Supply Companies and « Wound Care Centers Distributors s
Slide 11: Sales & Marketing Channels, Recent International Events
Sales & Marketing Channels, Recent International Events » Pharma Technology International Joint Venture to market, distribute and sell the CellerateRX products in 20 countries in Middle East and Northern Africa. — Initial order for Lebanon received in January 2010 — More orders in process (Saudi Ara
Slide 12: Corporate Expansion: eHealth Technology Acquired
Corporate Expansion, aacsHe eHealth Technology Acquired “Securing Healthcare One Step at a Time” > HIPAA/AARA compliant, secure and intelligent communications for healthcare entities to collaborate in a safe environment » Products include: — “envoiiHC” a revolutionary communications agent to: + Noti
Slide 13: Wound Care Innovations LLC
Wound Care Innovations LLC » The patented Activated Collagen found in CellerateRX® products is ideally prepared for immediate use by the body, and kick starts critical wound healing processes in the wound bed immediately. > These products are FDA cleared for the following indications: — pressure ulc
Slide 14: CellerateRX: More Information about some Indications
CellerateRX: More Information about some Indications > Pressure Ulcers (Stages I-IV) are prevalent in up to 28% of people in long term care facilities and home health » Diabetic Ulcers. Estimates continue to rise, currently it is predicted that over 7.1% of the world population will have diabetes by
Slide 15: Why CellerateRX
Why CellerateRX® >» Activated Collagen is a disruptive technology, enabling products which: » Out perform other collagen products; » Deliver unparalleled, comprehensive results as an active dressing capable of supporting natural debridement, managing infection, and controlling drainage while activel
Slide 16: Marketing - CellerateRX
Marketing - CellerateRX Our immediate market is the multi-billion dollar wound care market. Primary buyers include physicians, clinics, wound care centers, hospitals, homecare, long term care, hospice and DME. » FDAcleared for marketing for most wound types » Products have HCPC codes for Medicare Re
Slide 17: Wound Care Market Projections
United Statement Market U.S, market for advanced wound care technologies is estimated to grow at an average annual growth rate of 12.3% over the next 5 years to reach over $4.6 billion Source: BOCResearch 2007 Other Targeted Markets: iddle East Statement Market Saudi Arabia, a country of over 12 mil
Slide 18: Executive Team
Executive Team » Wound Management Technologies is led by a seasoned team of healthcare and business professionals. Scott Haire, Chairman, CEO Gilbert Valdez - Director: Deborah Jenkins Hutchinson, Steven Evans - Director President Lucy Singleton, CAO Robert Gross - Director Cathy Bradshaw, President
Slide 19: Corporate Resources
Corporate Resources The Company has very strong partners that will enable them to significantly expand the business as opportunities present themselves. > CPA(GAP) Evans ,Miller, Warriner and Company, PLLC (Barbourville, KY) > CPA (Audits) Pritchett, Siler, and Hardy, P.C. (Salt Lake City, UT) >» Le
Slide 20: Wound Management Technologies, Inc. contact
i\dmanagement technologies, inc. Biotech Products & Healthcare Technology Solutions 777 Main Street, Suite 3100 Fort Worth, Texas 76102 1-817-820-7080. Corporate 1-817-820-7076 Deborah Jenkins Hutchinson (direct) djenkins@wmgtech.com 1-954-315-9242 Wound Care Innovations, LLC 790 E. Broward Blvd, Su
Wound Management Technologies — Investor Presentation (March 2010) on 6ix